BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/16/2016 10:47:00 AM | Browse: 1368 | Download: 2225
 |
Received |
|
2016-03-16 08:46 |
|
Peer-Review Started |
|
2016-03-18 10:58 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2016-04-19 16:19 |
|
Revised |
|
2016-05-06 18:46 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2016-06-27 17:05 |
|
Second Decision by Editor-in-Chief |
|
2016-06-28 08:43 |
|
Final Decision by Editorial Office Director |
|
2016-07-18 11:05 |
|
Articles in Press |
|
2016-07-18 11:05 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2016-11-02 10:28 |
|
Publish the Manuscript Online |
|
2016-11-16 10:47 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article, which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
|
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Infectious Diseases |
| Manuscript Type |
Randomized Controlled Trial |
| Article Title |
Telbivudine <i>vs</i> tenofovir in hepatitis B e antigen-negative chronic hepatitis B patients: OPTIMA roadmap study
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Zahari Krastev, Diana Petrova, Iskren Kotzev, Mustafa Kemal Celen, Meryl Mendelson, Richa Chandra, Priti Pandey and Kamal Hamed |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Novartis Pharma AG |
|
|
| Corresponding Author |
Kamal Hamed, MD, MPH, Sr Worldwide Medical Director, Novartis Pharmaceuticals Corporation,
1 Health Plaza, East Hanover, NJ 07936,
United States. kamal.hamed@novartis.com |
| Key Words |
Chronic hepatitis B; Glomerular filtration rate; Telbivudine; Tenofovir; Roadmap concept |
| Core Tip |
This was the first prospective, randomised, non-inferiority study in hepatitis B e antigen-negative chronic hepatitis B patients that compared telbivudine and tenofovir administered as per roadmap concept. Both treatments based on the roadmap approach were effective over a 156 wk treatment period. Non-inferiority of telbivudine arm to tenofovir arm was demonstrated at week 52, with over 91% of patients in each treatment arm achieving hepatitis B virus DNA level < 300 copies/mL. Both treaments showed acceptable safety profiles. Moreover, telbivudine showed an improvement in estimated glomerular filtration rate from baseline. |
| Publish Date |
2016-11-16 10:47 |
| Citation |
Krastev Z, Petrova D, Kotzev I, Celen MK, Mendelson M, Chandra R, Pandey P, Hamed K. Telbivudine vs tenofovir in hepatitis B e antigen-negative chronic hepatitis B patients: OPTIMA roadmap study. World J Hepatol 2016; 8(32): 1402-1413 |
| URL |
http://www.wjgnet.com/1948-5182/full/v8/i32/1402.htm |
| DOI |
http://dx.doi.org/10.4254/wjh.v8.i32.1402 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
